Form 4: IOVANCE CMO's Routine Stock Vesting and Tax Withholding

IOVANCE Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• Chief Medical Officer Friedrich Graf Finckenstein reported transactions on March 2, 2026, related to his holdings in IOVANCE BIOTHERAPEUTICS, INC.
• 12,697 shares of common stock were acquired due to the vesting of restricted stock units (RSUs).
• 7,122 shares of common stock were disposed of at a price of $3.79 per share to satisfy mandatory tax withholding requirements upon the RSU vesting. This was not an open market sale.
• Following these reported transactions, the reporting person directly owns 117,231 shares of common stock.
• Derivative securities transactions included the vesting of 8,790 and 3,907 Restricted Stock Units.
• 35,159 RSUs granted on March 1, 2024, remain unvested, while all RSUs granted on March 2, 2023, have now fully vested.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction (RSU vesting and tax withholding) that does not indicate a change in the company's fundamental performance or outlook.

Positives

• The vesting of 12,697 shares of common stock for the Chief Medical Officer represents a routine compensation event, aligning executive incentives with shareholder value.

Negatives

• 7,122 shares were disposed of to cover tax obligations, which is a standard practice but results in a reduction of the officer's direct shareholdings.

Future Outlook

The remaining Restricted Stock Units (RSUs) held by the Chief Medical Officer will vest in equal quarterly installments.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Shares were withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

Industry Context

StockSavvy.ai notes that routine insider filings like Form 4, detailing RSU vesting and tax-related share dispositions, are common across the biotechnology sector as part of executive compensation packages. These transactions typically do not reflect a change in the company's operational performance or strategic direction but rather the execution of pre-established compensation plans.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of granting Restricted Stock Units (RSUs) as a component of executive compensation, with subsequent share withholding for tax purposes upon vesting, is a standard industry practice.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently utilize similar equity compensation structures to align executive incentives with long-term shareholder value.
• The specific share price of $3.79 for tax withholding is a market-determined value at the time of vesting, comparable to how other biotech firms handle similar events based on their respective stock prices.

Related Party Transactions

• The transaction involves the Chief Medical Officer (an insider) and the Issuer (IOVANCE BIOTHERAPEUTICS, INC.), representing a compensation-related dealing.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It reflects the ongoing alignment of executive incentives with company performance through equity.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Remaining RSUs granted on March 1, 2024, will vest in equal quarterly installments.

Key Dates

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Chief Medical Officer, Executive Compensation, Stock Withholding